<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00554762</url>
  </required_header>
  <id_info>
    <org_study_id>CBA110877</org_study_id>
    <nct_id>NCT00554762</nct_id>
  </id_info>
  <brief_title>Dose Response and Efficacy of GW842166 in Pain</brief_title>
  <official_title>A Phase I, Placebo Controlled, Randomised, Double Blind Two-way Crossover Study to Investigate the Dose Response and Efficacy of Single and Repeat Doses of GW842166 in Healthy Volunteers Using Pharmacodynamic Pain Assessments.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the dose response and efficacy of single and repeat
      doses of GW842166 in healthy volunteers using pharmacodynamic pain assessments.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Compound terminated
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">March 2008</completion_date>
  <primary_completion_date type="Anticipated">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Heat pain threshold at 5 hours post dose</measure>
    <time_frame>5 Hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Heat pain threshold at 3 hours post dose. • Mechanical pain threshold (using von Frey filaments) at 3 and 5 hours post dose.</measure>
    <time_frame>5 Hours</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW842166X</intervention_name>
    <description>Administer</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects aged 18 to 50 years inclusive

          -  Body Weight &gt;50 Kg and BMI within the range 18.5 to 32 kg/m2 inclusive.

          -  Women who are not of child bearing potential

        Exclusion Criteria:

          -  The subject has a positive pre-study urine screen for drugs of abuse or positive
             alcohol test.

          -  A positive pre-study (HIV), hepatitis B surface antigen or positive hepatitis C
             antibody result within 3 months of the start of the study.

          -  Abuse of alcohol defined as an average weekly intake of greater than 28 units (21
             units for women) or an average daily intake of greater than 3 units (2 units for
             women). 1 unit is equivalent to a half-pint (220 mL) of beer or 1 (25 mL) measure of
             spirits or 1 glass (125 mL) of wine.

          -  Where participation in study would result in donation of blood in excess of 500 mL
             within a 56 day period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2007</study_first_submitted>
  <study_first_submitted_qc>November 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2007</study_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mechanical pain,</keyword>
  <keyword>heat pain,</keyword>
  <keyword>dose,</keyword>
  <keyword>efficacy</keyword>
  <keyword>dose response,</keyword>
  <keyword>GW842166,</keyword>
  <keyword>Single,</keyword>
  <keyword>pharmacodynamics,</keyword>
  <keyword>repeat dose,</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

